ArticlePharmacoEconomics - open2022

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).

Lotte Westerink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.